MPS Pharmaa

Is MPS Pharmaa overvalued or undervalued?

As of November 12, 2024, MPS Pharmaa is considered risky and overvalued with a PE ratio of -5.22 and an EV to EBITDA of -2.59, indicating severe operational challenges and inefficiencies, despite a significant 666.67% return over the past five years, which is unsustainable compared to the Sensex's 211.54% return.

As of 12 November 2024, MPS Pharmaa's valuation grade has moved from does not qualify to risky, indicating a significant shift in its perceived financial health. The company is currently deemed overvalued, with a PE ratio of -5.22 and an EV to EBITDA of -2.59, both of which suggest severe operational challenges. Additionally, the ROCE stands at -48.75%, highlighting inefficiencies in capital utilization.<BR><BR>When compared to peers, MPS Pharmaa's metrics are starkly unfavorable. For instance, MMTC, also categorized as risky, has a PE ratio of 119.39, while Optiemus Infra, which is fairly valued, boasts a PE of 82.35. Notably, MPS Pharmaa's PEG ratio is 0.00, indicating no expected growth, further reinforcing its overvaluation status. Despite a remarkable 666.67% return over the past five years, this performance contrasts sharply with the broader market, as evidenced by the Sensex's 211.54% return over the same period, suggesting that MPS Pharmaa's current price may not be sustainable given its financial metrics.

What is the technical trend for MPS Pharmaa?

As of May 27, 2025, MPS Pharmaa shows a mildly bullish trend in daily moving averages, but longer-term indicators like weekly and monthly MACD, KST, and Bollinger Bands suggest a mixed outlook with bearish signals.

As of 27 May 2025, the technical trend for MPS Pharmaa has changed from mildly bearish to mildly bullish. The daily moving averages indicate a mildly bullish stance, while the weekly and monthly MACD and KST remain mildly bearish. The Bollinger Bands reflect a mildly bearish trend on the weekly and bearish on the monthly. The Dow Theory shows no trend on the weekly and mildly bearish on the monthly. Overall, the current technical stance is mildly bullish, but the strength is tempered by bearish signals in longer time frames.

Who are in the management team of MPS Pharmaa?

As of March 2019, the management team of MPS Pharmaa includes Peeyush Kumar Aggarwal (Managing Director), Manoj Kumar Jain and Madhu Sharma (Independent Directors), Pooja Chuni (Company Secretary), and Ram Niwas Sharma (Director). They are responsible for the company's governance and operations.

As of March 2019, the management team of MPS Pharmaa includes the following individuals:<BR><BR>1. Peeyush Kumar Aggarwal - Managing Director<BR>2. Manoj Kumar Jain - Independent Director<BR>3. Pooja Chuni - Company Secretary<BR>4. Madhu Sharma - Independent Director<BR>5. Ram Niwas Sharma - Director<BR><BR>These members play key roles in the governance and operations of the company.

What does MPS Pharmaa do?

MPS Pharmaa Ltd is a micro-cap company in the Pharmaceuticals & Biotechnology sector, focusing on ethical, generic, and over-the-counter drugs. As of September 2024, it reported a net profit of -2 Cr and has a market cap of INR 6 Cr.

Overview:<BR>MPS Pharmaa Ltd operates in the Pharmaceuticals & Biotechnology industry as a micro-cap company, focusing on the development and production of ethical, generic, and over-the-counter drugs.<BR><BR>History:<BR>MPS Pharmaa Ltd was established with the goal of achieving USFDA standards of quality. The latest quarterly results reported are for September 2024, indicating a net profit status.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: N/A<BR>Most recent Net Profit: -2 Cr (Quarterly Results - Sep 2024)<BR>Market-cap value: INR 6 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: N/A (Loss Making)<BR>Industry P/E: 27<BR>Dividend Yield: 0.00%<BR>Debt-Equity: 3.69<BR>Return on Equity: -51.30%<BR>Price-to-Book: 2.92<BR><BR>Contact Details:<BR>Address: 138 Roz-Ka-Meo Industrial Area, Sohna Mewat Haryana : 122103<BR>Tel: 91-124-2362471/2014471<BR>Email: mail@advikindia.com<BR>Website: http://www.mpspharmaa.com

Who are the top shareholders of the MPS Pharmaa?

The top shareholders of MPS Pharmaa are Omkam Pharmaceuticals Private Limited with 25.65%, Pataliputra International Limited at 17.51%, and individual investors holding a combined 36.05%. There are currently no mutual funds or foreign institutional investors involved.

The top shareholders of MPS Pharmaa include Omkam Pharmaceuticals Private Limited, which holds the largest share at 25.65%. Following that, Pataliputra International Limited is the highest public shareholder with a stake of 17.51%. Additionally, individual investors collectively hold 36.05% of the shares. Notably, there are no mutual funds or foreign institutional investors currently holding shares in the company.

How has been the historical performance of MPS Pharmaa?

MPS Pharmaa has experienced a consistent decline in financial performance from 2020 to 2025, with worsening reserves, decreasing shareholder funds, and negative profit before tax in multiple years, indicating ongoing operational and liquidity challenges. The book value per share fell from Rs 4.38 in 2020 to Rs 0.57 in 2025.

Answer:<BR>The historical performance of MPS Pharmaa shows a consistent decline in key financial metrics over the years, particularly from 2020 to 2025.<BR><BR>Breakdown:<BR>MPS Pharmaa's share capital has remained stable at Rs 19.11 crore from 2020 to 2025, while total reserves have worsened, moving from -10.75 crore in 2020 to -18.03 crore in 2025. Shareholder's funds have also decreased significantly, dropping from Rs 8.36 crore in 2020 to just Rs 1.08 crore in 2025. The company has maintained no long-term borrowings throughout this period, indicating a lack of debt financing. However, total liabilities have decreased from Rs 16.41 crore in 2020 to Rs 9.33 crore in 2025, primarily due to a reduction in current liabilities. The total assets have similarly declined from Rs 16.41 crore in 2020 to Rs 9.33 crore in 2025, with a notable drop in net current assets, which have remained negative, indicating ongoing liquidity issues. The book value per share has also fallen from Rs 4.38 in 2020 to Rs 0.57 in 2025, reflecting the company's deteriorating financial health. Profit before tax has been negative in several years, with a loss of Rs 1 crore in 2023 and Rs 4 crore in 2021, while cash flow from operating activities has consistently been zero or negative, highlighting ongoing operational challenges.

When is the next results date for MPS Pharmaa?

The next results date for MPS Pharmaa is 14 November 2025.

The next results date for MPS Pharmaa is scheduled for 14 November 2025.

Should I buy, sell or hold MPS Pharmaa Ltd?

Why is MPS Pharmaa Ltd falling/rising?

As of 03-Apr, the stock price of MPS Pharmaa Ltd is Rs 1.65, unchanged from the previous session, with a monthly decline of 4.62% and a year-to-date drop of 10.81%. The company's high debt-to-equity ratio and negative EBITDA indicate significant financial risk and poor long-term growth prospects.

As of 03-Apr, the stock price of MPS Pharmaa Ltd is currently at Rs 1.65, showing no change from the previous trading session. The stock has experienced a decline of 4.62% over the past month and a year-to-date decrease of 10.81%. This downward trend is further highlighted by the company's weak long-term fundamentals, indicated by a high debt-to-equity ratio of 6.9 times, which suggests significant financial risk. <BR><BR>Additionally, the company has reported negative earnings before interest, taxes, depreciation, and amortization (EBITDA) of Rs -0.76 crore, and its operating profit has stagnated at 0% over the last five years. The flat results reported in December, with the lowest PBDIT and PBT figures, further contribute to the stock's poor performance. <BR><BR>While there has been a notable increase in delivery volume, which rose by 1271.95% against the 5-day average, the overall trading environment has been challenging, with the stock underperforming compared to the benchmark Sensex, which has fallen by 2.60% over the past week. The stock is also close to its 52-week low, being only 4.85% away from Rs 1.57. <BR><BR>In summary, the combination of high debt, negative EBITDA, and poor long-term growth prospects are key factors contributing to the stock's decline.

Why is MPS Pharmaa Ltd falling/rising?

As of 04-Apr, MPS Pharmaa Ltd's stock price is stable at Rs 1.65, but it has declined 10.81% year-to-date and shows weak financial health with a high debt-to-equity ratio and negative EBITDA, indicating a challenging environment for the stock.

As of 04-Apr, MPS Pharmaa Ltd's stock price is currently stable at Rs 1.65, showing no change (0.00%). Despite this stability, the stock has experienced a decline of 10.81% year-to-date and a 4.62% drop over the past month, indicating a general downward trend. The stock has also underperformed compared to the Sensex, which has fallen by 13.96% year-to-date.<BR><BR>The stock's performance today has outperformed its sector by 3.04%, but it is still close to its 52-week low, being only 4.85% away from Rs 1.57. This suggests that while there may be some positive movement today, the overall sentiment remains weak. The stock has shown erratic trading patterns, having not traded on 5 out of the last 20 days, which may contribute to investor uncertainty.<BR><BR>Additionally, the company's financial health raises concerns. MPS Pharmaa Ltd has a high debt-to-equity ratio of 6.9 times, indicating significant leverage and weak long-term fundamental strength. The company has reported negative EBITDA of Rs -0.76 crore and flat results in December 2025, with net sales and operating profit growth stagnating over the last five years. These factors contribute to the perception of the stock as risky, further influencing its price stability and potential decline.<BR><BR>In summary, while there is a slight positive performance today, the overall trend for MPS Pharmaa Ltd is downward due to high debt levels, poor financial results, and erratic trading, which collectively suggest a challenging environment for the stock.

Why is MPS Pharmaa Ltd falling/rising?

As of 05-Apr, MPS Pharmaa Ltd's stock price is Rs 1.65, unchanged from the previous session, with a monthly decline of 4.62% and a year-to-date drop of 10.81%. The company's high debt-to-equity ratio and negative EBITDA indicate significant financial risk, contributing to its bearish trend and making it a risky investment.

As of 05-Apr, MPS Pharmaa Ltd's stock price is currently at Rs 1.65, showing no change from the previous trading session. The stock has experienced a decline of 4.62% over the past month and a year-to-date drop of 10.81%. This downward trend is further highlighted by the company's weak long-term fundamentals, including a high debt-to-equity ratio of 6.9 times, which indicates significant financial risk. The company has also reported negative EBITDA of Rs -0.76 crore, reflecting poor operational performance.<BR><BR>Despite some positive indicators, such as a 1271.95% increase in delivery volume on 16 March compared to the 5-day average, the overall performance remains concerning. The stock is currently 4.85% away from its 52-week low, and it has underperformed the sector by 3.04% today. Additionally, the stock's moving averages indicate it is lower than the 5-day, 20-day, 50-day, and 100-day averages, suggesting a bearish trend.<BR><BR>Overall, the combination of high debt, negative earnings, and poor sales growth contributes to the stock's decline, making it a risky investment.

Which are the latest news on MPS Pharmaa?